Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04954014
Other study ID # BEVACOR
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date September 1, 2020
Est. completion date August 31, 2021

Study information

Verified date August 2021
Source Maimónides Biomedical Research Institute of Córdoba
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Our hypothesis is that treating ARDS caused by COVID-19 with bevacizumab improves mortality. This is a phase II, multi-centered, randomized, open label, two-armed clinical trial to study the safety and efficacy of bevacizumab in COVID-19 positive patients who consequently developed ARDS (acute respiratory distress syndrome) and who have previously received anti-viral and anti-inflammatory treatment.


Description:

The vascular endothelial growth factor (VEGF) improves vascular capillarity, which plays an important role in the uncontrolled inflammatory reaction that happens in ARDS. As opposed to this event, angiogenic therapy (like bevacizumab) is known to contribute to normal vascularization, relevant for regaining vascular permeability. Studies in animal models have shown that treating ARDS with anti-VEGF therapy is effective.


Recruitment information / eligibility

Status Terminated
Enrollment 21
Est. completion date August 31, 2021
Est. primary completion date August 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Age equal or over 18 and under 90 years old. - Confirmed COVID-19 positive diagnostic through PCR. - Radiological image compatible with non-cardiogenic bilateral pleuropulmonary exudate. - Patient has received anti-viral and anti-inflammatory therapy. - Present any of the following clinical-functional criteria: 1. Respiratory distress: Tachypnea> 30 breaths / minute 2. Partial arterial oxygen pressure (PaO2) / Fraction of inspiration (FiO2) = 300 mmHg - Signed informed consent, directly or delegated. Exclusion Criteria: - Severe liver dysfunction (Child Pugh = 3 or AST> 5 times normal) - Severe renal dysfunction with glomerular filtration <30 mL / minute or under treatment with hemodialysis or peritoneal dialysis. - Poorly controlled hypertension (BPs> 160 mmHg or TAd <100 mmHg) or having a history previous hypertensive crisis or hypertensive encephalopathy. - History of poorly controlled heart disease with a NYHA> 2. - History of thrombosis in the previous 6 months. - Signs of active bleeding. - Open wounds, gastrointestinal perforation. - Diagnosis of thrombophilic diseases or hemorrhagic diathesis. - Active viral hepatitis or HIV not properly treated. - Intolerance or allergy to bevacizumab or its components. - Pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Bevacizumab
Patients will receive best available treatment (BAT) for COVID-19 plus a single dose of bevacizumab calculated as 7,5 mg/kg diluted in 250cc of saline solution during 90 minutes.
BAT
Patients will receive best available treatment for COVID-19.

Locations

Country Name City State
Spain Hospital Universitario Reina Sofía Córdoba Córdona

Sponsors (1)

Lead Sponsor Collaborator
Maimónides Biomedical Research Institute of Córdoba

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mortality Mortality After 28 days
Secondary PaO2/FiO2 Ratio calculation 6 hours before bevacizumab administration and 24 hours,72 hours,7 days,14 days and 28 days after.
Secondary Clinical improvement according to scale recommended by WHO for COVID19 Clinical improvement according to WHO scale (World Health Organization) for COVID19 which goes from 1 to 7 points. 24 hours, 72 hours, 7 days, 14 days and 28 days after treatment.
Secondary Time to clinical improvement as stated in the National Early Warning Score 2 (NEWS) NEWS assesses clinical risk on a scale of 1 (low) to 8 (high) From randomization until improvement of 2 points in the scale or until hospital discharge, whatever happens first, assessed up to 28 days.
Secondary Time to improvement of oxygenation Improvement shown during, at least, 48 hours. From randomization until outcome event assessed up to 28 days.
Secondary Time to improvement of Sp2/O2 ratio regarding the worst Sp2/O2 ratio obtained before bevacizumab treatment. Time to improvement of Sp2/O2 ratio regarding the worst Sp2/O2 ratio obtained before bevacizumab treatment From randomization until first documented Sp2/O2 ratio improvement, assessed up to 28 days.
Secondary Time to absence of oxygen need to maintain a saturation equal or over 93% Time to absence of oxygen need to maintain a saturation equal or over 93% From randomization until patient doesn't need oxygen to mantain 93% saturation, assessed up to 28 days.
Secondary Favorable radiological evaluation. Dictated by 3 radiologists. From randomization until first documented radiology improvement, assessed up to 28 days.
See also
  Status Clinical Trial Phase
Completed NCT04369456 - Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients N/A
Completed NCT04527471 - Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 Phase 2
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Withdrawn NCT04383899 - Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Completed NCT04532632 - Taste and Smell Impairment in Critically Ill COVID-19 Patients
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Completed NCT04413435 - Clinical Characteristics of Critically Ill Patients With COVID-19
Terminated NCT05593770 - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Phase 2/Phase 3
Completed NCT04510493 - Canakinumab in Patients With COVID-19 and Type 2 Diabetes Phase 3
Active, not recruiting NCT04587219 - The Study of "Gam-COVID-Vac" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older Phase 2
Withdrawn NCT05430958 - Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers Phase 1
Completed NCT04596579 - SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
Completed NCT04405934 - COG-UK Project Hospital-Onset COVID-19 Infections Study N/A
Enrolling by invitation NCT04484025 - SPI-1005 Treatment in Moderate COVID-19 Patients Phase 2
Terminated NCT04442230 - NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) Phase 2
Terminated NCT04642638 - Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure Phase 2/Phase 3
Active, not recruiting NCT04527432 - COVID-19 Health Professional Impact Study N/A